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Background: Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with increased rates of restenosis-
related endpoints as well as adverse safety endpoints compared to PCI in non-DM patients.
Methods: We examined outcomes related to the Endeavor zotarolimus-eluting stent (ZES) compared with the TAXUS paclitaxel-eluting stent (PES) 
in 477 patients with DM enrolled in the ENDEAVOR IV trial. Outcomes included three-year rates of target lesion revascularization (TLR), target vessel 
revascularization (TVR), and target vessel failure (TVF), as well as other key safety endpoints including cardiac death, myocardial infarction (MI), and 
stent thrombosis.
Results: Baseline characteristics were largely similar among ZES (n=241) and PES (n=236) patients. Consistent with one-year data, three-year 
rates of TLR and TVR remained similar between ZES and PES (TLR: 9.7% vs. 8.6%, p=0.72; TVR: 14.0% vs. 15.3%, p=0.71). Despite similar rates 
of TVR, there was a trend towards lower TVF among ZES (15.4% vs. 21.1%, p=0.13), driven by numerically lower rates of cardiac death (1.4% vs. 
4.1%, p=0.08) and MI (1.3% vs. 3.7%, p=0.12), with lower rates of composite cardiac death/MI (2.7% vs. 7.3%, p=0.03). The incidence of definite/
probable stent thrombosis was similar in both groups (3 events vs. 2 events, p=0.67).
Conclusions: Despite the higher risk conferred by DM, ZES had similar efficacy to PES in single de novo lesions, with trends toward improved safety 
at three years.
